Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis

Connect Biopharma Holdings Ltd

Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.
Connect eligible for up to $110M in remaining development, regulatory, and commercial milestone payments.
Connect also eligible for tiered royalties up to low double-digit percentages on Greater China net sales.
Rademikibart is a next-generation IL-4Rα antibody; AD market in China estimated at 70M patients.
Connect retains all rights outside Greater China under the 2023 license agreement with Simcere.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.